BioZapetite x 90 Vegetable Capsules X
Regular price
Rs. 27,984
- Unit price
- per
100% Authentic
Made in USA
Authorised distributor
1-5 Days delivery
BioZapetite x 90 Vegetable Capsules
Regular price
Rs. 27,984
- Unit price
- per
Price includes all duties and taxes
SKU: SUPP-BIOZEP
FMI's Choice
BioZapetite - Oral GLP-1 Receptor Agonist Research Compound (6 mg)
BioZapetite delivers orforglipron (6 mg), a first-in-class oral, small-molecule GLP-1 receptor agonist. Unlike peptide-based GLP-1 agonists, orforglipron is orally bioavailable without fasting or water restrictions and demonstrates robust pharmacology in glucose regulation, weight reduction, and cardiometabolic health.
Mechanistic Claims
- Glucose Disposal & Insulin Sensitivity
- Enhances glucose-dependent insulin secretion.
- Suppresses glucagon release.
- Improves post-prandial glucose control.
- Weight Reduction & Appetite Control
- Activates central satiety signaling pathways.
- Slows gastric emptying.
- Consistently reduces caloric intake.
- Lipid & Cardiometabolic Health
- Secondary benefits of weight loss include reductions in blood pressure, triglycerides, and waist circumference.
- Oral Dosing Convenience
- Half-life of ~29–49 hours supports once-daily dosing.
- No need for co-formulated absorption enhancers.
- Safety Profile
-
- Consistent with injectable GLP-1 agonists.
- Predominantly mild-to-moderate GI events during titration.
- No hepatic safety signal observed in Phase 3 readouts.
Research Applications
- Appetite regulation and body weight studies
- Glucose disposal and glycemic control investigations
- Cardiometabolic risk reduction models
- Oral small-molecule incretin pharmacology
- Translational safety and GI tolerability research
Research Insights
Glucose Disposal & Glycemic Control
In a 26-week multicentre trial in type 2 diabetes (n=383), orforglipron reduced HbA1c up to –2.10% and body weight by –10.1 kg, significantly outperforming placebo and matching/exceeding dulaglutide at higher doses [3]. A 12-week Phase 1b trial reported HbA1c reductions of –1.5% to –1.8% with up to –5.8 kg weight loss [4].
Appetite & Weight Regulation
In a 36-week obesity study, orforglipron produced –9.4% to –14.7% weight reduction vs –2.3% with placebo, with 46–75% of participants achieving ≥10% weight loss depending on dose [1][2]. Improvements were observed in all prespecified cardiometabolic measures, including waist circumference, blood pressure, and lipid markers.
Oral Pharmacology & PK
Unlike oral peptide GLP-1 formulations, orforglipron does not require an absorption enhancer or fasting. AUC and Cmax decrease ~18–24% with food, but this is not clinically significant [6]. Half-life ~29–49 h supports once-daily dosing [4].
Safety & Tolerability
Across Phase 2 and Phase 3 programs, the safety profile was consistent with injectable GLP-1 RAs. GI events (nausea, diarrhea, dyspepsia, vomiting) were most common and dose-related, occurring mainly during titration [3][5]. In Phase 3 (ACHIEVE-1), discontinuations due to AEs were 4–8% vs 1% with placebo, and no hepatic safety signals were detected [5].
References
- Wharton S, et al. NEJM 2023. Orforglipron in obesity: –9.4% to –14.7% weight loss at 36 weeks; improvements in cardiometabolic measures. https://pubmed.ncbi.nlm.nih.gov/37351564/
- Wharton S, et al. NEJM 2023. Dose-dependent weight loss (–8.6% to –12.6% at 26 weeks) in obesity without diabetes. https://pubmed.ncbi.nlm.nih.gov/37351564/
- Frias JP, et al. Lancet 2023. Phase 2 T2D: HbA1c ↓ up to –2.10%; weight ↓ up to –10.1 kg; greater efficacy than dulaglutide at high dose. https://cardiometabolicforum.com/publications/99
- Pratt E, et al. Diabetes Obes Metab 2023. Phase 1b: HbA1c –1.5% to –1.8%, weight loss –5.8 kg; t½ ~29–49 h. https://pubmed.ncbi.nlm.nih.gov/37264711/
-
Lilly Press Release 2025. Phase 3 ACHIEVE-1: HbA1c ↓ –1.3% to –1.6%; weight ↓ –7.9%; GI AEs dose-related; no hepatic signal. https://www.prnewswire.com/news-releases/lillys-oral-glp-1-orforglipron-demonstrated-statistically-significant-efficacy-results-and-a-safety-profile-consistent-with-injectable-glp-1-medicines-in-successful-phase-3-trial-302430985.html
- Ma X, et al. Diabetes Therapy 2024. Food-effect PK: AUC/Cmax ↓ ~18–24% fed vs fasted; overall well-tolerated; no SAEs. https://link.springer.com/article/10.1007/s13300-024-01554-1
Label--
| Supplement Facts Serving Size: 1 Capsule Servings per Container: 90 |
|
| Ingredient | Amount Per Serving |
| Orforglipron | 6 mg |
Dosage--For Research Purposes Only
This content is provided strictly for research purposes and does not constitute an endorsement or recommendation for the non-laboratory application or improper handling of peptides designed for research. The information, including discussions about specific peptides and their researched benefits, is presented for informational purposes only and must not be construed as health, clinical, or legal guidance, nor an encouragement for non-research use in humans. Peptides described here are solely for use in structured scientific study by authorized individuals. We advise consulting with research experts, medical practitioners, or legal counsel prior to any decisions about obtaining or utilizing these peptides. The expectation of responsible, ethical utilization of this information for legitimate investigative and scholarly objectives is paramount. This notice is dynamic and governs all provided content on research peptides
Store in a dry and dark place at room temperature, out of reach of small children.
Additional Taxes may apply for shipping to GCC
100% Authentic
Made in USA
Authorised distributor
1 - 5 days delivery
Click to read - How we deliver to India
Disclaimer
Product Information Sheet
: Not a diet substitute. Seek Medical guidance if unsure before use.
BioZapetite - Oral GLP-1 Receptor Agonist Research Compound (6 mg)
BioZapetite delivers orforglipron (6 mg), a first-in-class oral, small-molecule GLP-1 receptor agonist. Unlike peptide-based GLP-1 agonists, orforglipron is orally bioavailable without fasting or water restrictions and demonstrates robust pharmacology in glucose regulation, weight reduction, and cardiometabolic health.
Mechanistic Claims
- Glucose Disposal & Insulin Sensitivity
- Enhances glucose-dependent insulin secretion.
- Suppresses glucagon release.
- Improves post-prandial glucose control.
- Weight Reduction & Appetite Control
- Activates central satiety signaling pathways.
- Slows gastric emptying.
- Consistently reduces caloric intake.
- Lipid & Cardiometabolic Health
- Secondary benefits of weight loss include reductions in blood pressure, triglycerides, and waist circumference.
- Oral Dosing Convenience
- Half-life of ~29–49 hours supports once-daily dosing.
- No need for co-formulated absorption enhancers.
- Safety Profile
-
- Consistent with injectable GLP-1 agonists.
- Predominantly mild-to-moderate GI events during titration.
- No hepatic safety signal observed in Phase 3 readouts.
Research Applications
- Appetite regulation and body weight studies
- Glucose disposal and glycemic control investigations
- Cardiometabolic risk reduction models
- Oral small-molecule incretin pharmacology
- Translational safety and GI tolerability research
Research Insights
Glucose Disposal & Glycemic Control
In a 26-week multicentre trial in type 2 diabetes (n=383), orforglipron reduced HbA1c up to –2.10% and body weight by –10.1 kg, significantly outperforming placebo and matching/exceeding dulaglutide at higher doses [3]. A 12-week Phase 1b trial reported HbA1c reductions of –1.5% to –1.8% with up to –5.8 kg weight loss [4].
Appetite & Weight Regulation
In a 36-week obesity study, orforglipron produced –9.4% to –14.7% weight reduction vs –2.3% with placebo, with 46–75% of participants achieving ≥10% weight loss depending on dose [1][2]. Improvements were observed in all prespecified cardiometabolic measures, including waist circumference, blood pressure, and lipid markers.
Oral Pharmacology & PK
Unlike oral peptide GLP-1 formulations, orforglipron does not require an absorption enhancer or fasting. AUC and Cmax decrease ~18–24% with food, but this is not clinically significant [6]. Half-life ~29–49 h supports once-daily dosing [4].
Safety & Tolerability
Across Phase 2 and Phase 3 programs, the safety profile was consistent with injectable GLP-1 RAs. GI events (nausea, diarrhea, dyspepsia, vomiting) were most common and dose-related, occurring mainly during titration [3][5]. In Phase 3 (ACHIEVE-1), discontinuations due to AEs were 4–8% vs 1% with placebo, and no hepatic safety signals were detected [5].
References
- Wharton S, et al. NEJM 2023. Orforglipron in obesity: –9.4% to –14.7% weight loss at 36 weeks; improvements in cardiometabolic measures. https://pubmed.ncbi.nlm.nih.gov/37351564/
- Wharton S, et al. NEJM 2023. Dose-dependent weight loss (–8.6% to –12.6% at 26 weeks) in obesity without diabetes. https://pubmed.ncbi.nlm.nih.gov/37351564/
- Frias JP, et al. Lancet 2023. Phase 2 T2D: HbA1c ↓ up to –2.10%; weight ↓ up to –10.1 kg; greater efficacy than dulaglutide at high dose. https://cardiometabolicforum.com/publications/99
- Pratt E, et al. Diabetes Obes Metab 2023. Phase 1b: HbA1c –1.5% to –1.8%, weight loss –5.8 kg; t½ ~29–49 h. https://pubmed.ncbi.nlm.nih.gov/37264711/
-
Lilly Press Release 2025. Phase 3 ACHIEVE-1: HbA1c ↓ –1.3% to –1.6%; weight ↓ –7.9%; GI AEs dose-related; no hepatic signal. https://www.prnewswire.com/news-releases/lillys-oral-glp-1-orforglipron-demonstrated-statistically-significant-efficacy-results-and-a-safety-profile-consistent-with-injectable-glp-1-medicines-in-successful-phase-3-trial-302430985.html
- Ma X, et al. Diabetes Therapy 2024. Food-effect PK: AUC/Cmax ↓ ~18–24% fed vs fasted; overall well-tolerated; no SAEs. https://link.springer.com/article/10.1007/s13300-024-01554-1
| Supplement Facts Serving Size: 1 Capsule Servings per Container: 90 |
|
| Ingredient | Amount Per Serving |
| Orforglipron | 6 mg |
For Research Purposes Only
This content is provided strictly for research purposes and does not constitute an endorsement or recommendation for the non-laboratory application or improper handling of peptides designed for research. The information, including discussions about specific peptides and their researched benefits, is presented for informational purposes only and must not be construed as health, clinical, or legal guidance, nor an encouragement for non-research use in humans. Peptides described here are solely for use in structured scientific study by authorized individuals. We advise consulting with research experts, medical practitioners, or legal counsel prior to any decisions about obtaining or utilizing these peptides. The expectation of responsible, ethical utilization of this information for legitimate investigative and scholarly objectives is paramount. This notice is dynamic and governs all provided content on research peptides
Store in a dry and dark place at room temperature, out of reach of small children.
